価格
  1. 米国企業
  2. Orgenesis Inc.
  3. Raw

Orgenesis Inc.【ORGS】

時価総額
$286.9万
PER
ポイントオブケア型細胞療法プラットフォームの新興企業。自動化POCare技術や分散型細胞処理を展開。2022年11月にMetalmarkが約3,020万ドル出資、2024年4月にOMPUL資産売却で約8,340ドルの取引。北米・欧州・アジアに展開。
株価業績
サマリーテーブルに戻る
2011年
11月30日		2012年
11月30日		2014年
11月30日		2015年
11月30日		2016年
11月30日		2017年
11月30日		2018年
11月30日		2019年
12月31日		2020年
12月31日		2021年
12月31日		2022年
12月31日		2023年
12月31日
Net loss-72,352------19-26-1-18-12-65
Stock-based compensation-31133433210
Capital gain, net-------0-0-00-
Loss from deconsolidation of Octomera (see Note 3)------------5
Share in net loss of associated companies-------1-0-0-2-1
Depreciation and amortization expenses----33341222
Credit loss on convertible loan receivable-----------3
Impairment of investment-----------1
Impairment of intangible assets----------1-
Effect of exchange differences on inter-company balances---------1010
Net changes in operating leases---------0000
Interest expense accrued on loans and convertible loans------------2
Loss from extinguishment in connection with convertible loan-----0-----2-0-0
Accounts receivable---10-03511221-30
Prepaid expenses, other accounts receivable--------10-0-0
Inventory---000100-000
Other assets------------0
Related parties, net-----------0
Accounts payable44,513135,791111-1-152-4-16
Accrued expenses and other payable----------021
Employee and related payables---------00-00
Deferred taxes, net--------1-0-0
Net cash used in operating activities-189-1,051,612-1,429,247-3-4-4-16-13-78-27-25-15
Repayment of convertible loan to related party partners----------1-
Decrease in loan to associate entities-----------0
Increase in loan to associate entities----------4-
Sale of property, plants and equipment-------00-0-
Purchase of property, plants and equipment-9,6794,74611161228122
Investment in associated company---------0-1
Cash acquired from acquisition of Mida----------1-
Impact to cash resulting from deconsolidation (see Note 3)-----------1
Increase in cash from business combinations of TLABS and Orgenesis Austria----------0-
Investment in long-term deposits----------00
Net cash used in investing activities--20,9772,509-1-2-3-6-14106-12-14-4
Proceeds from issuance of shares due to exercise of options and warrants (net of transaction costs)--------9225
Proceeds from issuance of convertible loans--21262110-196
Proceeds from transaction with redeemable non-controlling interest that do not result in a loss of control, see note 3-------13--205
Repayment of convertible loans and convertible bonds-----40-2123
Repayment of short and long-term debt------010000
Proceeds from issuance of loans payable-----------1
Grant received in respect of third party----------1-
Transfer of the grant received to third party----------1-
Net cash provided by financing activities55,0001372835246-04014
NET CHANGE IN CASH AND CASH EQUIVALENTS AND RESTRICTED CASH--------333-391-5
EFFECT OF EXCHANGE RATE CHANGES ON CASH AND CASH EQUIVALENTS--------0-0-00
Right-of-use assets obtained in exchange for new operation lease liabilities-------8---1
Increase (decrease) in accounts payable related to purchase of property, plant and equipment-----------00
Loan conversion for Redeemable non-controlling interest (See note 3)----------10-
Issuance of common stocks in connection with the acquisition of Mida----------0-
Extinguishment in connection with convertible loan restructuring----------00
Interest-------0--01